Beam Therapeutics Inc.
23.21
-2.33 (-9.12%)
At close: Jan 14, 2025, 3:59 PM
23.21
0.00%
After-hours Jan 14, 2025, 07:01 PM EST
undefined%
Bid 22
Market Cap 1.92B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.58
PE Ratio (ttm) -14.69
Forward PE n/a
Analyst Buy
Ask 24
Volume 2,033,777
Avg. Volume (20D) 1,196,014
Open 25.50
Previous Close 25.54
Day's Range 22.80 - 25.61
52-Week Range 20.84 - 49.50
Beta undefined

About BEAM

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 6, 2020
Employees 472
Stock Exchange NASDAQ
Ticker Symbol BEAM

Analyst Forecast

According to 10 analyst ratings, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is $48, which is an increase of 106.81% from the latest price.

Buy 60.00%
Hold 40.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Beam Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $15.12M, reflecting a -95.22% YoY shrinking and earnings per share of -1.28, making a -173.99% decrease YoY.
1 month ago · Source
+5.49%
Beam Therapeutics shares are trading higher. The c... Unlock content with Pro Subscription
2 months ago · Source
+11.24%
Beam Therapeutics shares are trading higher after Leerrink Partners upgraded the stock from Market Perform to Outperform and raised its price target from $27 to $39.